{"title":"Charcot revived.","authors":"Hélio A G Teive","doi":"10.1055/s-0045-1804489","DOIUrl":"https://doi.org/10.1055/s-0045-1804489","url":null,"abstract":"","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 6","pages":"1-2"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A moral history of seizures: reported causes of seizures in the nineteenth century.","authors":"Márcio Pinheiro Lima, Elza Márcia Targas Yacubian","doi":"10.1055/s-0045-1806829","DOIUrl":"https://doi.org/10.1055/s-0045-1806829","url":null,"abstract":"<p><p>In the nineteenth century, neurology was in its infancy as an organized medical specialty. At that time, seizures were often attributed, under the guise of scientific explanations, to moral causes or behaviors. The medical literature from this period contains references to poor parental care as a cause of epilepsy and descriptions of seizures being inherited alongside other undesirable traits. Temperance was praised, while gluttony was associated with epileptic fits. Unwanted sexual behaviors, such as masturbation, were also considered a risk factor for seizures. Women were thought to be more prone to epilepsy due to their behaviors and emotional disposition. These accounts illustrate the interplay between neurological science and the prevailing social norms of the era.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 6","pages":"1-3"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption.","authors":"Jonathan M Schott, Charles R Marshall","doi":"10.1055/s-0045-1807718","DOIUrl":"https://doi.org/10.1055/s-0045-1807718","url":null,"abstract":"<p><p>The licensing of lecanemab and donanemab, disease-modifying immunotherapies for Alzheimer's disease (AD) targeting β-amyloid pathology, has been met with difference in opinion about efficacy, adverse effects, and cost-effectiveness. Here we summarize the current situation and make the case for cautious adoption of these treatments into clinical practice. This opinion is predicated on four main observations: 1) these treatments impact the core pathologies of AD and result in meaningful benefits; 2) while adverse effects can be serious, these are proving manageable in clinical practice; 3) upscaling services to deliver these agents is likely to provide wider benefits for diagnosing and treating dementia and facilitating the adoption of future treatments from the dementia drug pipeline; and 4) factoring in both the wider societal cost of care and potential for continued accrual of long term benefits will be likely to bring these treatments within acceptable cost-effectiveness thresholds.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-4"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Paula Hamad, Carla Andrea Tanuri Cardoso Caldas, Isabella Cristina Mendes de Sá E Silva, Marina Estima Neiva Nunes
{"title":"Could minor neurological dysfunction be a type of non-cerebral palsy motor impairment?","authors":"Ana Paula Hamad, Carla Andrea Tanuri Cardoso Caldas, Isabella Cristina Mendes de Sá E Silva, Marina Estima Neiva Nunes","doi":"10.1055/s-0045-1809359","DOIUrl":"https://doi.org/10.1055/s-0045-1809359","url":null,"abstract":"<p><p>Non-cerebral palsy motor impairments have been increasing over time, especially in preterm-born children, with a variety of labels, including, but not limited to, developmental coordination disorder and minor neurological dysfunction. They may not only negatively affect the child in their daily life activities, but are also associated with cognitive, emotional, and behavioral disorders, as well as decreased academic performance. Since there is a paucity of literature on non-cerebral palsy motor impairment, the main objective of the present study is to assess minor neurological dysfunction in the context of neurodevelopment. We reviewed the medical literature using the following search terms: <i>preterm infants</i>; <i>follow-up</i>; <i>non-cerebral palsy motor impairment or disability</i>; <i>minor neurological dysfunction</i>; <i>developmental coordination disorder</i>; <i>neurological soft signs</i>; and <i>Touwen Neurological Examination</i>. We compiled evidence-based data on minor neurological dysfunction critical domains, diagnosis, etiological factors and the influence of age and puberty in minor neurological signs. We also listed the cohort studies that used the Touwen Neurological Examination for premature or term-born follow-up, including those that suggest an association between minor neurological dysfunction and developmental coordination disorder as a motor impairment beyond cerebral palsy. Moreover, we found significant evidence of a correlation involving minor neurological dysfunction and cognitive, behavioral, and learning abilities, which, all in all, means that these children particularly deserve special attention regarding social, educational and healthcare resources. Furthermore, since motor activity seems to play an important role in the physical, mental, and neurological health of typical children, different approaches to education could have a positive impact on neurological development.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-11"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease.","authors":"Ricardo Nitrini, Adalberto Studart-Neto","doi":"10.1055/s-0045-1808082","DOIUrl":"10.1055/s-0045-1808082","url":null,"abstract":"<p><p>Two antiamyloid monoclonal antibodies (mAbs), lecanemab and donanemab, were recently launched for treatment of Alzheimer's disease (AD). These mAbs remove amyloid protein from the brain and cause statistically significant improvement in cognitive/functional tests, meaning a change in evolution of AD. This is important to reinforce the amyloid cascade hypothesis and to further concentrate studies on the pathways from the deposition of the beta-amyloid protein to synaptic loss and neuronal death. However, it is necessary to evaluate whether the results are clinically important. Analysis of the clinical trials showed that the statistically significant differences over placebo did not reach the minimum clinically important difference that would be meaningful for patients, caregivers and clinicians. Besides, the incidence of adverse events is high and potentially severe. Although there are reasons to celebrate this first step towards disease-modifying therapies for AD, lecanemab and donanemab should not be used to treat AD in clinical pratice.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-5"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Otto Jesus Hernández Fustes, Cláudia Suemi Kamoi Kay, Paulo José Lorenzoni, Renata Dal-Prá Ducci, Paula Raquel do Vale Pascoal Rodrigues, Rosana Herminia Scola
{"title":"Paul Hoffmann and the cutaneous silent period test.","authors":"Otto Jesus Hernández Fustes, Cláudia Suemi Kamoi Kay, Paulo José Lorenzoni, Renata Dal-Prá Ducci, Paula Raquel do Vale Pascoal Rodrigues, Rosana Herminia Scola","doi":"10.1055/s-0045-1806826","DOIUrl":"https://doi.org/10.1055/s-0045-1806826","url":null,"abstract":"<p><p>We herein present aspects of the biography of Professor Paul Hoffmann, covering his main works, mainly the article describing the cutaneous silent period, a new technique when it was published in 1922, with a review of its importance, its role in clinical neurophysiology, and its clinical application.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-3"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Irapuá Ferreira Ricarte, Ícaro Araújo de Sousa, Romilto Costa Pacheco Neto, Arthur de Oliveira Veras, Camila Victória da Silva, Cristina Calmon de Araújo Mascarenhas, Matheus Felipe da Silva, Gisele Sampaio Silva, Octávio Marques Pontes-Neto
{"title":"Telemedicine transforming stroke care in Piauí: an analysis of a state-wide initiative's first year.","authors":"Irapuá Ferreira Ricarte, Ícaro Araújo de Sousa, Romilto Costa Pacheco Neto, Arthur de Oliveira Veras, Camila Victória da Silva, Cristina Calmon de Araújo Mascarenhas, Matheus Felipe da Silva, Gisele Sampaio Silva, Octávio Marques Pontes-Neto","doi":"10.1055/s-0045-1807719","DOIUrl":"https://doi.org/10.1055/s-0045-1807719","url":null,"abstract":"<p><p>Prior to October 2022, stroke patients in Piaui lacked access to both stroke unit care and thrombolytic treatment, until the implementation of a telemedicine-based stroke care program.To conduct a descriptive analysis of patients suspected of stroke who received telemedicine-based care in Piauí during the first year of the program's implementation.We conducted a retrospective analysis of 868 patients treated from October 2022 to September 2023 under the state-wide stroke care program, which includes 6 Stroke Treatment Centers distributed around the state. Utilizing data from the JOIN telemedicine platform, the analysis focused on patient demographics, stroke types, treatment timelines, and outcomes of thrombolytic treatment.The cohort included 868 patients, with a mean age of 67.2 years, out of whom 55.5% were male. Chronic hypertension was reported in 57.8% and diabetes in 22.5% of the patients. The average onset-to-door time was 3.3 hours, door-to-computed tomography time was 23 minutes, and door-to-needle time averaged 67 minutes. Thrombolysis was administered to 15.6% of all stroke cases, with 31.8% among those being ischemic strokes. Among patients who arrived within the thrombolytic time window, the rate was 27.3%.The introduction of a telemedicine-based stroke care program in Piauí has significantly enhanced access to essential stroke treatments, demonstrating its effectiveness in overcoming healthcare disparities. The initiative's success underscores the potential of telemedicine as a scalable model for improving stroke care in regions with limited healthcare resources. Future efforts will focus on reducing treatment times and expanding stroke care infrastructure to ensure comprehensive patient care.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-7"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Antiamyloid therapies for Alzheimer's disease: an experts' dialogue on facts and controversies.","authors":"Paulo Caramelli","doi":"10.1055/s-0045-1808083","DOIUrl":"https://doi.org/10.1055/s-0045-1808083","url":null,"abstract":"","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-2"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marco Antonnio Rocha Dos Santos, Pierludovico Moro, Abner Lucas Balduino de Souza, Lauren Nirta, Thaís Pereira Mendes, Laura de Lima Xavier, Ming-Chieh Ding
{"title":"Endovascular thrombectomy for large-core stroke: a meta-analysis with trial sequential analysis.","authors":"Marco Antonnio Rocha Dos Santos, Pierludovico Moro, Abner Lucas Balduino de Souza, Lauren Nirta, Thaís Pereira Mendes, Laura de Lima Xavier, Ming-Chieh Ding","doi":"10.1055/s-0045-1806827","DOIUrl":"10.1055/s-0045-1806827","url":null,"abstract":"<p><p>Recent studies have reported that endovascular thrombectomy (ET) may improve neurological outcomes in large-core stroke.We performed a systematic review and meta-analysis to compare the pooled efficacy and safety of ET and of the best medical treatment among patients with large-core stroke.We searched the PubMed/MEDLINE, Scopus, and Cochrane databases from inception to November 2023. The inclusion criteria were randomized controlled trials (RCTs) comparing ET and the best medical treatment available among patients with large-core stroke (Alberta Stroke Program Early Computed Tomography Score [ASPECTS] < 6 or ischemic core > 50 mL on perfusion imaging) within 24 hours of symptom onset.We included 6 RTCs comprising 1,887 patients (ET group: <i>n</i> = 945). Endovascular thrombectomy was associated with good neurological outcomes (odds ratio [OR]: 2.92; 95% confidence interval [95%CI]: 2.17-3.93), or independent walking (OR: 2.22; 95%CI: 1.72-2.86). Trial sequential analysis confirmed a robust statistical significance for good neurological outcomes favoring ET. Endovascular thrombectomy was associated with higher risks of developing intracranial bleeding (OR: 2.65; 95%CI: 1.35-5.22) and symptomatic intracranial bleeding (OR: 1.83; 95%CI: 1.14-2.94). There were no differences between the groups regarding mortality or decompressive craniectomy. Patients submitted to non-contrast computed tomography (CT) with CT angiography (CTA) scans were analyzed separately and showed good neurological outcomes, comparable to those of the patients submitted to other imaging modalities (OR: 3.24; 95%CI: 1.52-6.92).Endovascular thrombectomy was associated with good neurological outcomes and independent walking in patients with large-core acute ischemic stroke. However, it was also associated with an increased risk of developing intracranial bleeding. Non-contrast head CT with CTA scans may be appropriate for screening patients to undergo ET.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-12"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luisa Couceiro de Albuquerque Macêdo, Raphaelly Ribeiro Campos, Luiz Eduardo Duarte Borges Nunes, Mariana Gonçalves Maciel Pinheiro, Alberto Henrique Torres Trindade da Silva, Maria Regina Vendas Carneiro Leão, Aldson Dos Santos Silva, Felipe Alves Mourato, Simone Cristina Soares Brandão, Breno José Alencar Pires Barbosa
{"title":"How the use of FDG PET is improving the diagnosis of dementia in a reference center in Recife, Brazil.","authors":"Luisa Couceiro de Albuquerque Macêdo, Raphaelly Ribeiro Campos, Luiz Eduardo Duarte Borges Nunes, Mariana Gonçalves Maciel Pinheiro, Alberto Henrique Torres Trindade da Silva, Maria Regina Vendas Carneiro Leão, Aldson Dos Santos Silva, Felipe Alves Mourato, Simone Cristina Soares Brandão, Breno José Alencar Pires Barbosa","doi":"10.1055/s-0045-1808086","DOIUrl":"https://doi.org/10.1055/s-0045-1808086","url":null,"abstract":"<p><p>Since the advent of 18F-2-fluoro-2-deoxy-D-glucose ([18F]FDG, henceforth, FDG) in the 1970s as a neurochemical tracer, FDG positron emission tomography (PET) has been used for research in dementia and to help diagnose dementing neurodegenerative disorders. However, FDG PET is still unavailable in most centers, especially those in low- and middle-income countries, and there is limited data on biomarkers from patients in diverse populations, such Latin Americans.To analyze the main indications and how the use of FDG PET helped improve the diagnosis of dementia in a specialized center in Recife, one of the largest cities in Northeastern Brazil.We retrospectively analyzed data from 62 individuals under follow-up at our center between 2018 and 2023 who had a clinical diagnosis of dementia or mild cognitive impairment and underwent FDG PET scans.In 21/29 (72.4%) patients, FDG PET helped investigate the types of atypical neurodegenerative dementias; in 14/24 (58.3%), it clarified the clinical question in the investigation of early-onset dementia syndromes; and, in 9 cases, it was performed to differentiate between degenerative and non-degenerative dementias.These numbers may set the foundation for further longitudinal analyses and collaborative studies including participants from Northeastern Brazil.</p>","PeriodicalId":8694,"journal":{"name":"Arquivos de neuro-psiquiatria","volume":"83 5","pages":"1-8"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}